Senores Pharmaceuticals Ltd

According to an exchange filing, the basket of acquired ANDAs consists of 13 USFDA-approved applications and one that is pending approval. The addressable market opportunity for these ANDAs in the U.S. is estimated at approximately USD 421 million (MAT December 2024), as per IQVIA, and around USD 1.13 billion (MAT September 2024), according to specialty data aggregator Symphony. The acquisition will be funded through the proceeds raised from Senores Pharmaceuticals' Initial Public Offer (IPO), in line with the objectives outlined in the Red Herring Prospectus. Swapnil Shah, Managing Director, Senores Pharmaceuticals, said, 'We are glad to announce the acquisition of a basket of products from Dr. Reddy's. It spans across various therapeutic areas with growing consumption. The portfolio consists of controlled substances and general categories of products. These products can be distributed through multiple/diverse channels, with large requirements in government, retail and specialty clinics. This portfolio of products significantly increases our product offering in the US, and it also has a significant value in other regulated and semi-regulated markets of the world.' Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024. Shares of Dr. Reddy's Laboratories rose 0.05% to Rs 1,120.40 on the BSE. Powered by Capital Market - Live

Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA (SPI), has signed agreements today to acquire a basket of 14 Abbreviated New Drug Applications (ANDAs) from Dr. Reddy's Laboratories and its applicable affiliates. The basket acquired, comprises of 13 ANDAs, which are approved by the USFDA and 1 ANDA, which is pending approval from the USFDA. The addressable opportunity of the acquired ANDAs in the USA is approx. USD 421 Million (MAT December 2024) as per IQVIA and ~ approx USD 1.13 Billion (MAT September 2024)# as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the Objects of the IPO stated in the Red Herring Prospectus.Powered by Capital Market - Live

The facility spans approximately 230,000 sq. ft. and has an installed capacity of 100 metric tons per year. This marks their second API manufacturing plant, significantly enhancing their existing API manufacturing capabilities. Swapnil Shah, MD, SenoresPharmaceuticals, said, 'We are delighted to commence operations at our Greenfield state-of-the-art API facility at Mehsana. Commissioning of this API facility will help Senores broaden its offerings and strengthen its competitiveness in the regulated markets, especially in the CDMO/CMO business.' Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024. Shares of Senores Pharma rose 0.34% to Rs 550.40 on the BSE.Powered by Capital Market - Live

Senores Pharmaceuticals has commenced manufacturing activities at its greenfield active pharmaceutical ingredient (API) plant at Mehsana, Gujarat. Spread across approximately 230,000 sq. ft. with an installed capacity of ~100 Metric Tons per Annum, this is Senores' second API manufacturing facility. Powered by Capital Market - Live

Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International that markets, distributes, and sells generic pharmaceuticals in the United States. Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe Chronic Obstructive Pulmonary Disease (COPD) associated with chronic bronchitis and a history of exacerbations. The market size of Roflumilast in the USA was approximately $32 million (MAT June 2024) as per IQVIA and around $46 million (MAT September 2024) as per the specialty data aggregator Symphony. The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the objects of the IPO stated in the red herring prospectus. Swapnil Shah, managing director, Senores Pharmaceuticals, said, 'We are excited to announce the acquisition of the Roflumilast tablet ANDA from Breckenridge Pharmaceutical, Inc. This strategic acquisition of Roflumilast Tablet ANDA, for which the manufacturing will be done locally at our US site, expands our portfolio into specialty distribution and also helps us establish a presence in the chronic bronchitis therapy area. This aligns with our strategic focus on identifying and entering a niche, under-penetrated generic formulations with an opportunity to serve the unmet needs in healthcare.' Senores Pharmaceuticals (Senores) is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms. The company's consolidated net profit surged 142% to Rs 17.18 crore in Q3 FY25 as compared with Rs 7.10 crore in Q3 FY24. Net sales jumped 30.9% YoY to Rs 103.02 crore during the quarter ended 31st December 2024.Powered by Capital Market - Live

Profit before tax stood at Rs 20.48 crore in the December 2024 quarter, up 99.61% from Rs 10.26 crore in the same quarters last year. In Q3 FY25, regulated market business revenues stood at Rs 70.2 crore, registering a growth of 2.5% compared to Rs 68.4 crore in Q3 FY24. Emerging markets business revenues surged 289.3% to Rs 26.1 crore, up from Rs 6.7 crore in Q3 FY24. EBITDA in Q3 FY25 soared 92% to Rs 29.1 crore as compared to Rs 15.2 crore reported in Q3 FY24. EBITDA margin improved 27.3% during the quarter as against 19.2% in the same quarter previous year. On a nine-month basis, the company's net profit rallied 117.86% to Rs 40.37 crore on 153.43% jump in revenue from operations to Rs 284.04 crore in 9M FY25 over 9M FY24. Swapnil Shah, managing director of Senores Pharmaceuticals, said, 'We are pleased to report strong performance for Q3 and 9MFY25, driven by our strategy of developing niche products for regulated markets and expanding our CDMO/CMO operations. At the same time, we have continued to grow our presence and product portfolio in emerging markets. In Regulated Markets, robust growth in the CDMO/CMO segment was partlyoffset by a softer performance in the Marketed Products segment, which wasimpacted by the high base of Q3FY24. The consolidation of acquired businesses has resulted in strong growth in the Emerging Markets segment for Q3FY25. Year-on-year, the Regulated Markets and Emerging Markets businesses grew by approximately 100% and over 10 times, respectively, for 9MFY25. In 9M FY25, we launched one new product and received ANDA approval forfive products in the Regulated Markets business, bringing our total ANDA approvals to 24. We are seeing significant traction and scale-up in our CDMO/CMO segment. Currently, we manufacture 21 products in this business and expect faster growth with the addition of new products, customers, and increased wallet share from existing customers. We remain focused on executing our business strategies across segments and are confident that healthy growth will continue in the year ahead.' Senores Pharmaceuticals gaged in developing and manufacturing a wide range of pharmaceutical products, predominantly for the regulated markets of the US, Canada, and United Kingdom across various therapeutic areas and dosage forms, with a presence in emerging markets. Powered by Capital Market - Live

Net profit of Senores Pharmaceuticals rose 141.97% to Rs 17.18 crore in the quarter ended December 2024 as against Rs 7.10 crore during the previous quarter ended December 2023. Sales rose 30.90% to Rs 103.02 crore in the quarter ended December 2024 as against Rs 78.70 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales103.0278.70 31 OPM %24.9419.25 - PBDT24.6913.50 83 PBT20.4910.25 100 NP17.187.10 142 Powered by Capital Market - Live

Senores Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 23 January 2025.Powered by Capital Market - Live

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker, and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. According to IQVIA and Symphony sales data for the 12-month period ending November 2024, the Metoprolol Tartrate and Hydrochlorothiazide Tablet USP 50 mg/25 mg and 100 mg/25 mg markets achieved annual sales of approximately $ 6 million and $ 10 million, respectively, it added. Senores' current portfolio includes 24 ANDA products that are permitted for distribution in the USA. In addition to these internal filings, Senores is actively seeking external development collaborations to augment and accelerate the growth of its existing pipeline and portfolio. Swapnil Shah, MD, Senores Pharmaceuticals, said, 'We have been relentlessly working in enhancing our product portfolio, which includes a wide range of specialty and complex pharmaceutical products across various therapeutic areas in regulated markets, particularly in the US. Metoprolol Tartrate and Hydrochlorothiazide are specialized formulations with limited competition in the US, providing us an opportunity to capture a higher market share in this region.' Senores Pharmaceuticals is engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the regulated markets of the US, Canada, and the United Kingdom across various therapeutic areas and dosage forms, with a presence in emerging markets. The company identifies and develops a diverse range of specialty, underpenetrated, and complex pharmaceutical products and manufactures critical care injectables and APIs. As of September 30, 2024, the company has launched 55 products in key therapeutic areas, including antibiotics and anti-fungal treatments. The firm reported a consolidated net profit of Rs 23.94 crore and sales of Rs 181.02 crore for the six months ended on 30 September 2024. Shares of Senores Pharmaceuticals declined 2.03% to currently trade at Rs 520 on the BSE.Powered by Capital Market - Live

Senores Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA) for marketing Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg. Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate, a beta adrenoceptor blocker and hydrochlorothiazide (HCTZ), a thiazide diuretic, indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. According to IQVIA and Symphony sales data for the 12-month period ending November 2024, the Metoprolol Tartrate and Hydrochlorothiazide Tablet USP, 50 mg/25 mg and 100 mg/25 mg market achieved annual sales of approximately $ 6 million and $ 10 million respectively. Senores' current portfolio includes 24 ANDA products that are permitted for distribution in the USA. In addition to these internal filings, Senores is actively seeking external development collaborations to augment and accelerate the growth of its existing pipeline and portfolio.Powered by Capital Market - Live